Ibrexafungerp for Vulvovaginal Candidiasis
A randomized clinical trial compared one day of oral ibrexafungerp with placebo for female patients with vulvovaginal candidiasis (VVC). It found ibrexafungerp to be safe and effective, with mild diarrhea the most common adverse event. Ibrexafungerp differs mechanistically from azoles and appears to be a promising new treatment for VVC.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.